The impact of using different symptom-based exacerbation algorithms in patients with COPD

European Respiratory Journal

Volumn 37, Issue 5, 2011, Pages 1260-1268

  Trappenburg, J C A ^a   Van Deventer, A C ^a   Troosters, T ^b   Verheij, T J M ^a   Schrijvers, A J P ^a   Lammers, J W J ^a   Monninkhof, E M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Chronic obstructive pulmonary disease; Chronic obstructive pulmonary disease exacerbations

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID;

AGED; CHEST TIGHTNESS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLASSIFICATION ALGORITHM; COUGHING; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DYSPNEA; EARLY DIAGNOSIS; FATIGUE; FEMALE; FEVER; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SPUTUM ANALYSIS; SYSTEMATIC REVIEW; WHEEZING;

AGED; ALGORITHMS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX;

EID: 79955646901     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00130910     Document Type: Review

References (35)

1. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532-555. (Pubitemid 47403272)
2. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000; 117: 398S-401S.
3. Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1418-1422.
4. Donaldson GC, Seemungal TA, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847-852. (Pubitemid 35178607)
5. Soler-Cataluna JJ, Martinez-Garcia MA, Roman SP, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60: 925-931. (Pubitemid 41598207)
6. Miravitlles M, Murio C, Guerrero T, et al. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 2002; 121: 1449-1455. (Pubitemid 34499654)
7. Aaron SD, Fergusson D, Marks GB, et al. Counting, analysing and reporting exacerbations of COPD in randomised controlled trials. Thorax 2008; 63: 122-128. (Pubitemid 351236474)
8. Sapey E, Stockley RA. COPD exacerbations. 2: aetiology. Thorax 2006; 61: 250-258.
9. Langsetmo L, Platt RW, Ernst P, et al. Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort. Am J Respir Crit Care Med 2008; 177: 396-401. (Pubitemid 351317582)
10. Seemungal TA, Donaldson GC, Bhowmik A, et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161: 1608-1613. (Pubitemid 30329036)
11. Vijayasaratha K, Stockley RA. Reported and unreported exacerbations of COPD: analysis by diary cards. Chest 2008; 133: 34-41.
12. Xu W, Collet JP, Shapiro S, et al. Negative impacts of unreported COPD exacerbations on health-related quality of life at 1 year. Eur Respir J 2010; 35: 1022-1030.
13. Effing TW, Kerstjens HA, Monninkhof EM, et al. Definitions of exacerbations: does it really matter in clinical trials on COPD? Chest 2009; 136: 918-923.
14. Leidy NK, Wilcox TK, Jones PW, et al. Development of the EXAcerbations of Chronic Obstructive Pulmonary Disease Tool (EXACT): A Patient-Reported Outcome (PRO) Measure. Value Health 2010; 3: 965-975.
15. Leidy NK, Wilcox TK, Jones PW, et al. Standardizing measurement of COPD exacerbations: reliability and validity of a patientreported diary. Am J Respir Crit Care Med 2010; [Epub ahead of print DOI: 10.1164/rccm.201005-0762OC].
16. FDA Center for Drug evaluation and Research, FDA Center for Biologics Evaluation and Research, FDA Center for Devices and Radiological Health. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labelling Claims. Washington, US Department of Health and Human Services, 2009.
17. Trappenburg JC, Koevoets L, de Weert-van Oene GH, et al. Action Plan to enhance self-management and early detection of exacerbations in COPD patients; a multicenter RCT. BMC Pulm Med 2009; 9: 52.
18. Engels JM, Diehr P. Imputation of missing longitudinal data: a comparison of methods. J Clin Epidemiol 2003; 56: 968-976. (Pubitemid 37268084)
19. Suissa S. Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 173: 842-846.
20. Hurst JR, Donaldson GC, Quint JK, et al. Temporal clustering of exacerbations in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 179: 369-374.
21. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196-204. (Pubitemid 17009877)
22. Alvarez-Mon M, Miravitlles M, Morera J, et al. Treatment with the immunomodulator AM3 improves the health-related quality of life of patients with COPD. Chest 2005; 127: 1212-1218. (Pubitemid 46224283)
23. Ekberg-Jansson A, Larson M, MacNee W, et al. N-isobutyrylcysteine, a donor of systemic thiols, does not reduce the exacerbation rate in chronic bronchitis. Eur Respir J 1999; 13: 829-834. (Pubitemid 29234786)
24. Van Schayck CP, Dompeling E, van Herwaarden CL, et al. Continuous and on demand use of bronchodilators in patients with non-steroid dependent asthma and chronic bronchitis: fouryear follow-up randomized controlled study. Br J Gen Pract 1995; 45: 239-244.
25. Sund ZM, Powell T, Greenwood R, et al. Remote daily real-time monitoring in patients with COPD - a feasibility study using a novel device. Respir Med 2009; 103: 1320-1328.
26. Banerjee D, Khair OA, Honeybourne D. The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD. Respir Med 2005; 99: 208-215. (Pubitemid 40104276)
27. Calverley P, Pauwels DR, Lofdahl CG, et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. Eur Respir J 2005; 26: 406-413. (Pubitemid 41264201)
28. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 217-224. (Pubitemid 34162820)
29. Dowson LJ, Guest PJ, Stockley RA. The relationship of chronic sputum expectoration to physiologic, radiologic, and health status characteristics in a1-antitrypsin deficiency (PiZ). Chest 2002; 122: 1247-1255. (Pubitemid 35339537)
30. Pela R, Calcagni AM, Subiaco S, et al. N-acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD. Respiration 1999; 66: 495-500.
31. Dahl R, Chung KF, Buhl R, et al. Efficacy of a new once-daily longacting inhaled b2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax 2010; 65: 473-479.
32. Bhowmik A, Seemungal TA, Sapsford RJ, et al. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000; 55: 114-120. (Pubitemid 30245950)
33. Wilkinson TM, Donaldson GC, Hurst JR, et al. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 169: 1298-1303. (Pubitemid 39571857)
34. Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J 2003; 21: Suppl. 41, 46s-53s.
35. Wang C, Hall CB. Correction of bias from non-random missing longitudinal data using auxiliary information. Stat Med 2010; 29: 671-679.